Novartis says heart-failure drug wins faster review in Europe

ZURICH, Nov 28 (Reuters) - Novartis' new heart failure drug was granted a speedier evaluation by the European health regulator, shortening the review by 60 days, the Swiss drugmaker said on Friday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.